Kidney cancer drugs under the microscope: Real-World data from china

NCT ID NCT07024680

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks back at medical records of 150 Chinese adults with advanced papillary kidney cancer who were treated with sunitinib or sorafenib. Researchers want to see how long the cancer stays under control and how safe the drugs are in everyday practice. It is an observational study, meaning no new treatments are given—just data collected from past care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could provide real-world evidence on how well these drugs work for this type of kidney cancer in Chinese patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only looks back at past data, which can have missing or biased information.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAPILLARY RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

papillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAPILLARY RENAL CELL CARCINOMA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.